Nile Therapeutics promotes Darlene Horton to CEO and director
Article continues below
Dr. Horton served as Nile's Chief Medical Officer from June 2012 until her appointment as its CEO. Previously, she served as Chief Medical Officer of Itero Biopharmaceuticals, a venture-backed biosimilar company. Previous to Itero, Dr. Horton served as Senior Vice President, Clinical Research at Scios, Inc., a Johnson & Johnson (J&J) company.
During her 12 year tenure at Scios, she was the clinical lead for Natrecor, a commercial product indicated for the treatment of acute heart failure. Dr. Horton led the Natrecor program from late-stage development through FDA approval and commercialization, and was also part of the senior management team at the time of Scios's acquisition by J&J. Dr. Horton also served as the Head of the Cardiovascular Therapeutic Area Center of Excellence for J&J pharmaceutical companies. ■